News

India Has Banned 16 More Fixed Dose Combinations — The Health Ministry's FDC Rationalisation Continues as Patient Safety Takes Priority Over Market Convenience

By Darshan S, Editor · 25 June, 2026 · 2 min read

Summary

• India Bans 16 Fixed Dose Combinations: The Health Ministry's Continuing FDC Rationalisation Drive
• India's Health Ministry banned 16 Fixed Dose Combinations via Gazette Notification on June 11, 2026, including antibiotic-enzyme combos and multi-drug combinations lacking therapeutic justification.

"The risks associated with these fixed dose combinations outweigh their benefits. Combinations without sufficient therapeutic justification — including those combining antibiotic and enzyme preparations without clinical evidence of superior efficacy over individual components — represent a regulatory responsibility the Ministry is now systematically discharging."

The Government of India has notified the prohibition of manufacture, sale, and distribution of 16 Fixed Dose Combinations through a Gazette Notification issued on June 11, 2026, under Section 26A of the Drugs and Cosmetics Act, 1940 — the legal provision that authorises the Central Government to prohibit pharmaceutical products determined to be dangerous to public health or lacking therapeutic justification.

The banned combinations span a range of therapeutic categories and combination types. They include Amoxicillin + Serratiopeptidase + Lactobacillus Sporogenes, Amoxicillin + Serratiopeptidase, Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide, Acetyl Salicylic Acid + Ethoheptazine, and multiple topical formulations combining Aloe Vera with various agents including Jojoba Oil, Vitamin E, Dimethicone, Orange Oil, and Wheat Germ Oil — 16 distinct combinations found, in the government's determination, to carry risks outweighing benefits or to lack sufficient scientific evidence supporting their therapeutic superiority over the individual component drugs.

Why FDC Rationalisation Matters

Fixed dose combinations — pharmaceutical products that combine two or more active ingredients in a fixed ratio within a single dosage form — are not inherently irrational. Many FDCs provide genuine therapeutic advantages: co-administration of multiple drugs required together for a condition in a single tablet improves compliance and reduces pill burden. HIV antiretroviral combination tablets, fixed-dose anti-tuberculosis regimens, and anti-hypertensive combinations with proven clinical synergy are examples of FDCs that serve compelling clinical purposes.

But India's pharmaceutical market has historically tolerated a large number of FDCs that lack this justification — combinations where the fixed ratio has no pharmacological basis, where individual components don't need to be given simultaneously, where the combination provides no evidence of superior efficacy over separate administration, or where the combination creates unnecessary adverse effect risk by requiring patients to receive a component they may not need. The antibiotic-enzyme combination category is a prominent example: there is no established clinical evidence that adding serratiopeptidase to amoxicillin improves antibiotic outcomes, yet this combination has been widely marketed and prescribed in India for decades.

The Regulatory Trajectory

India's systematic FDC rationalisation began in earnest with the government's 2016 ban of 344 FDCs — a sweeping action that triggered legal challenges from pharmaceutical companies that argued the government had not followed due process through the Drugs Technical Advisory Board. Subsequent court rulings established the procedural requirements, and the government has since continued the rationalisation process through regular Gazette Notifications. Each new ban follows the Expert Committee and DTAB review process established by the courts.

The June 11, 2026 ban of 16 FDCs is the most recent action in this ongoing process. Pharmaceutical companies manufacturing any of the 16 combinations must immediately cease manufacture, sale, and distribution — and existing stocks may not be sold after the notification date, depending on the specific terms of the Gazette order.

The Patient Safety and Prescribing Quality Dimensions

FDC rationalisation has two distinct public health objectives. The first is patient safety: irrational combinations may expose patients to unnecessary drug exposure, drug interactions, or adverse effects from components that are not clinically indicated for their condition. The second is rational prescribing: the proliferation of combination products makes it more difficult for clinicians and patients to distinguish clinically justified combinations from marketing-driven combinations, and may contribute to antimicrobial resistance by promoting antibiotic use in irrational contexts.

The June 2026 ban includes combinations from both categories: combinations with safety concerns from irrational multi-drug combinations (particularly those combining CNS-active components like Clidinium + Chlordiazepoxide with antiinflammatory and antispasmodic agents), and combinations lacking therapeutic justification (antibiotic-enzyme combinations, multi-herbal topical combinations without established efficacy).

The Commercial Pharmaceutical Market Impact

Each FDC ban has commercial implications for the Indian pharmaceutical market: products are withdrawn, revenue from those specific formulations ceases, and manufacturing lines dedicated to banned combinations must be repurposed or shut down. For large pharmaceutical companies with diversified portfolios, individual FDC bans have limited financial impact. For smaller companies that depend significantly on a small number of FDC products, the commercial consequences can be more material.

"BHC Perspective"

At Bengaluru Health Community, India's FDC rationalisation is a pharmaceutical regulatory story that reflects the country's growing regulatory sophistication and its commitment to evidence-based pharmaceutical market oversight. For BHC founders in pharmaceutical formulation, regulatory consulting, or drug information technology — the FDC rationalisation programme creates both compliance requirements and commercial opportunities in the rational prescribing and evidence-based formulary management space.

Frequently Asked Questions

Q: What FDCs has India banned in June 2026?
A: 16 Fixed Dose Combinations via Gazette Notification dated June 11, 2026, including Amoxicillin + Serratiopeptidase (two combinations), Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide, Acetyl Salicylic Acid + Ethoheptazine, and multiple Aloe Vera-based topical combinations.

Q: Why does India ban Fixed Dose Combinations?
A: To eliminate irrational pharmaceutical combinations lacking sufficient therapeutic justification or carrying risks outweighing benefits — including combinations where components don't need to be given together, where no evidence supports the combination's superiority over individual drugs, or where combinations create unnecessary adverse effect risk.

Q: What is the broader FDC rationalisation context?
A: India's systematic FDC rationalisation began with a 2016 ban of 344 FDCs. The June 2026 action continues this process following established Expert Committee and DTAB review procedures — reflecting India's maturing pharmaceutical regulatory oversight capacity.